FY2025 Earnings Forecast for APLS Issued By Zacks Research

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Zacks Research issued their FY2025 earnings estimates for shares of Apellis Pharmaceuticals in a research report issued on Wednesday, November 19th. Zacks Research analyst Team expects that the company will post earnings per share of $0.17 for the year. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at ($0.43) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($0.33) EPS, Q2 2027 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.26) EPS and FY2027 earnings at ($1.06) EPS.

A number of other research analysts have also recently issued reports on APLS. Wells Fargo & Company initiated coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 15th. They set an “overweight” rating and a $32.00 price objective for the company. Mizuho lowered their price target on Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. The Goldman Sachs Group cut shares of Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $26.00 to $18.00 in a research note on Friday, September 26th. JPMorgan Chase & Co. reduced their price objective on shares of Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, Citigroup dropped their target price on shares of Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $33.06.

Apellis Pharmaceuticals Price Performance

APLS stock opened at $19.61 on Friday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The firm has a 50 day moving average price of $23.26 and a 200-day moving average price of $21.83. Apellis Pharmaceuticals has a 52-week low of $16.10 and a 52-week high of $35.72. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of 63.26 and a beta of 0.70.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, October 30th. The company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.03 by $0.64. The business had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. Apellis Pharmaceuticals’s quarterly revenue was up 133.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.46) earnings per share.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 49,963 shares of the stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $28.39, for a total value of $1,418,449.57. Following the transaction, the chief executive officer owned 307,946 shares of the company’s stock, valued at approximately $8,742,586.94. This represents a 13.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Timothy Eugene Sullivan sold 10,000 shares of the business’s stock in a transaction dated Tuesday, October 21st. The shares were sold at an average price of $28.03, for a total value of $280,300.00. Following the sale, the chief financial officer owned 110,936 shares of the company’s stock, valued at approximately $3,109,536.08. This represents a 8.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 312,921 shares of company stock worth $8,452,166 in the last three months. 6.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in APLS. CIBC Bancorp USA Inc. bought a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at $1,533,000. CANADA LIFE ASSURANCE Co raised its holdings in Apellis Pharmaceuticals by 186.8% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 17,747 shares of the company’s stock worth $402,000 after purchasing an additional 11,558 shares during the period. Caxton Associates LLP purchased a new position in Apellis Pharmaceuticals during the third quarter valued at $248,000. Woodline Partners LP lifted its position in Apellis Pharmaceuticals by 2.3% during the third quarter. Woodline Partners LP now owns 542,981 shares of the company’s stock valued at $12,288,000 after purchasing an additional 12,058 shares in the last quarter. Finally, PharVision Advisers LLC bought a new stake in Apellis Pharmaceuticals during the third quarter valued at about $504,000. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).